| [1] |
Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 71(3), 209-249.
|
| [2] |
Fisher B．From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century[J]．Eur J Cancer，1999，35(14)：1963-1973.
|
| [3] |
van Maaren MC，de Munck L，de Bock GH, et al.10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study[J]．Lancet Oncol，2016，17(8)：1158-1170.
|
| [4] |
Chen K，Pan Z，Zhu L, et al.Comparison of breast-conserving surgery and mastectomy in early breast cancer using observational data revisited: a propensity score-matched analysis[J]．Sci China Life Sci，2018，61(12)：1528-1536.
|
| [5] |
Bernstein MB，Krishnan S，Hodge JW, et al.Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach？[J]．Nat Rev Clin，2016，13(8)：516-524.
|
| [6] |
Vanpouille-Box C，Formenti SC，Demaria S．Toward precision radiotherapy for use with immune checkpoint blockers[J]．Clin Cancer Res，2018，24(2)：259-265.
|
| [7] |
Sherene L，Steven D. Pilot study of stereotactic ablation for oligometastatic breast neoplasia in combination with the anti-PD-1 antibody MK-3475[EB/OL]. [2021-04-29].
URL
|
| [8] |
Steven C. Study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors[EB/OL]．[2021-04-29]．
URL
|
| [9] |
Christopher B. Study to assess the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer patients[EB/OL]．[2021-04-29].
URL
|
| [10] |
Sara T. Phase Ⅱ pembrolizumab + palliative radiotherapy in BC[EB/OL]. [2021-04-29].
URL
|
| [11] |
Adams S，Gatti-Mays ME，Kalinsky K，et al.Current landscape of immunotherapy in breast cancer: a review[J]．JAMA Oncol，2019，5(8)：1205-1214.
|
| [12] |
Barkal AA，Brewer RE，Markovic M，et al.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]．Nature，2019，572(7769)：392-396.
|
| [13] |
Garner H，de Visser KE.Immune crosstalk in cancer progression and metastatic spread: a complex conversation[J]．Nat Rev Immunol，2020，20(8)：1-15.
|
| [14] |
Derks MGM, van de Velde CJH.Neoadjuvant chemotherapy in breast cancer: more than just downsizing[J]．Lancet Oncol，2018，19(1)：2-3.
|
| [15] |
Pusztai L，Foldi J，Dhawan A，et al.Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers[J]．Lancet Oncol，2019，20(7)：e390-e396.
|
| [16] |
Gianni L，Eiermann W，Semiglazov V, et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J]．Lancet Oncol，2014，15(6)：640-647.
|
| [17] |
Schmid P，Cortes J，Pusztai L，et al.Pembrolizumab for early triple-negative breast cancer[J]．N Engl J Med，2020，382(9)：810-821.
|
| [18] |
Diver E，Dorigo O, Berek J．ASCO 2019 meeting review[EB/OL]．[2021-01-15]．
URL
|
| [19] |
Heil J, Pfob A, Sinn H, et al. Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: Oral presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, program number GS5-03[J]. Ann Surg，2022，275(3)：576-581.
|
| [20] |
Tan W, Liang G, Xie X, et al.Incorporating microRNA into molecular phenotypes of circulating tumor cells enhances the prognostic accuracy for patients with metastatic breast cancer[J]．Oncologist，2019，24(11)：e1044-e1054.
|
| [21] |
Liang G，Ling Y，Mehrpour M, et al.Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression[J]．Mol Cancer，2020，19(1)：65.
|
| [22] |
Liu Z，Zhou Y，Liang G, et al.Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p[J]．Cell Death Dis，2019，10(2)：55.
|
| [23] |
Li S，Lai H，Liu J, et al.Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy[J]．JCO Precis Oncol，2020，4：PO.19.00292.
|
| [24] |
魏兵，杨文涛．乳腺癌新辅助治疗的病理诊断专家共识(2020版)[J]．中华病理学杂志，2020(4)：296-304.
|
| [25] |
Masuda N，Lee SJ，Ohtani S，et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]．N Engl J Med，2017，376(22)：2147-2159.
|
| [26] |
von Minckwitz G，Huang CS，Mano MS, et al.Trastuzumab emtansine for residual invasive HER-2-positive breast cancer[J]．N Engl J Med，2019，380(7)：617-628.
|
| [27] |
Gong C，Tan W，Chen K, et al.Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER-2-negative breast cancer[J]．EBioMedicine，2016，11：199-209.
|
| [28] |
Badwe R，Hawaldar R，Nair N, et al.Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]．Lancet Oncol，2015，16(13)：1380-1388.
|
| [29] |
Soran A，Ozmen V，Ozbas S, et al.Randomized trial comparing resection of primary tumor with no surgery in stage iv breast cancer at presentation: Protocol MF07-01[J]．Ann Surg Oncol，2018，25(11)：3141-3149.
|
| [30] |
Modi S，Saura C，Yamashita T, et al.Trastuzumab deruxtecan in previously treated her2-positive breast cancer[J]．N Engl J Med，2020，382(7)：610-621.
|
| [31] |
Domchek SM.Risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers: a complex discussion[J]．JAMA，2019，321(1)：27.
|
| [32] |
Ramaswami R，Morrow M，Jagsi R．Contralateral prophylactic mastectomy[J]．N Engl J Med，2017，377(13)：1288-1291.
|
| [33] |
Wong SM，Freedman RA，Sagara Y, et al.Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer[J]．Ann Surg，2017，265(3)：581-589.
|
| [34] |
Tung NM，Boughey JC，Pierce LJ, et al.Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline[J]．J Clin Oncol，2020，38(18)：2080-2106.
|